Inhibition of Pterygium Fibroblast Migration and Outgrowth by Bevacizumab and Cyclosporine A Involves Down-Regulation of Matrix Metalloproteinases-3 and -13

Yeoun-Hee Kim, Jae-Chang Jung, Sang Il Gum, Su-Bin Park, Jin Yeul Ma, Yong Il Kim, Kyoo Won Lee, Young Jeung Park

1 Cheil Eye Research Institute, Cheil Eye Hospital, 1 Ayang-Ro, Dong-Gu, Daegu, Republic of Korea, 2 Korean Medicine (KM)-Application Center, Korea Institute of Oriental Medicine (KIOM), Cheomdan-ro Dong-gu, Daegu, Republic of Korea, 3 Department of Biology, College of Natural Sciences, Kyungpook National University, Daegu, Republic of Korea

☯ These authors contributed equally to this work.
* eyepark9@naver.com

Abstract

We examined the connection between matrix metalloproteinase (MMP) expression/activity and pterygium fibroblast migration, and how these were affected by bevacizumab and/or cyclosporine A (CsA). Fibroblasts were obtained from 20 pterygia and 6 normal conjunctival specimens. Expression levels of MMP-3 and MMP-13 were examined after bevacizumab administration. Immunofluorescence staining was used to examine expression of both MMPs in fibroblasts migrating out from explanted pterygium tissues. Rates of cell migration from explant-cultured pterygium tissues and scratch-wounded confluent pterygium fibroblasts were examined in the presence of MMP-3 or MMP-13 inhibitors, as well as bevacizumab and/or CsA. A scratch wound healing migration assay was performed to determine the effects of bevacizumab and/or CsA. Protein expression of both MMPs in pterygium tissues and in cells migrating from organ-cultured pterygium tissues was greater than that observed in normal cells. Inhibition of the activities of both MMPs significantly reduced their expression levels; these were also significantly reduced in bevacizumab-injected pterygium tissues. Bevacizumab significantly reduced the expression of both MMPs and cell migration. Pretreatment with CsA prior to bevacizumab exposure markedly inhibited cell migration and the expression of both MMPs. CsA enhanced the inhibitory effects of bevacizumab on pterygium fibroblast migration in vitro, possibly by inhibiting expression of both MMPs. These findings suggest that combined CsA and bevacizumab treatment may provide a potential therapeutic strategy for reducing the rate of pterygium recurrence.
**Introduction**

Pterygium is a common ocular surface disease in humans that is attributed to chronic ultraviolet-B exposure and can cause vision loss. It results from the migration of abnormal limbal basal epithelial stem cells (pterygium cells) into Bowman’s layer (BL) and causes the dissolution of this layer. Pterygium is characterized by high vascularization, proliferation, invasive ocular surface lesions, and aberrant extracellular matrix (ECM) remodeling [1–5]. Surgical excision is the standard treatment for a pterygium, but despite advances in surgical techniques, the pterygium recurrence rate is high [6–11].

Matrix metalloproteinases (MMPs) are zinc-dependent endopeptidases that are able to degrade all components of the ECM in connective tissues [12, 13]. They are important in various physiological and pathological processes, including tissue remodeling, wound healing, angiogenesis, cell invasion, and differentiation [14]. It has been suggested that MMPs play a role in pterygium formation because excessive fibroblast proliferation and invasion occur at the head of a pterygium, with BL and corneal stroma destruction [15]. Pterygium cells produce the MMPs that dissolve BL, thus stimulating the growth of stromal fibroblasts [4]. The overexpression of MMPs in altered limbal basal epithelial cells (pterygium cells) may be the primary cause of pterygium progression [16]. ECM modulation by MMPs may occur early in the course of pterygium invasion [3, 17]. Given that many studies have shown a strong association between MMPs and tumor progression/invasion [18], the invasive nature of the pterygial lesion is likely to involve altered MMP activity.

MMPs are expressed by a variety of cell types and they are categorized into five groups, based on their substrate specificity and cellular localization. These groups are the collagenases (MMP-1, -8, -13), the gelatinases (MMP-2, -9), the stromelysins (MMP-3, -10, -21, -22), the membrane-type MMPs (MT-MMPs), and the others [1, 19]. Increased levels of MMP-1, MMP-2, MMP-3, MMP-7 (matrilysin), MMP-8, and MMP-9 have been reported in pterygia [1, 5, 14, 20–25]. In particular, pterygium cells may also cause the activation of fibroblasts at the head of the pterygium, leading to cleavage of the fibrillar collagen in BL due to the production of high levels of active MMP-1 and MMP-3 [22, 24]. Expression of MMP-1 has been detected in pterygium fibroblasts found between the corneal epithelium and BL at the edge of the advancing pterygium [26]. Elevated levels of several other MMPs (MMP-2, MMP-3, MMP-7, MMP-8, MMP-9, and MMP-14) have also been detected in the pterygium, particularly at the advancing head [17, 24, 25]. The increased expression of multiple types of MMP and their release by pterygium cells facilitate invasion by degrading components of the BL and the adjacent stromal matrix [22, 26, 27]. Furthermore, it has been suggested that ECM degradation releases a range of cytokines including vascular endothelial growth factor (VEGF) and fibroblast growth factor; these stimulate angiogenesis, as well as the migration and proliferation of pterygium cells [14].

VEGF is involved in angiogenesis and has been detected in pterygia [28–31]. MMP-3 has also been clearly implicated in angiogenesis because it influences the generation of angiotatin, and an MMP-3 inhibitor was shown to inhibit angiogenic responses [32–34]. Importantly, MMP-3 can degrade many ECM because it has broad substrate specificity or activates other pro-MMPs such as MMP-1, MMP-9, and MMP-13, and it also plays a role in cell migration and angiogenesis [5, 35, 36]. During wound healing, MMP-13 is involved in a range of biological functions that include inflammatory responses, cell movement, angiogenesis, and proteolysis [37]. Recombinant MMP-13 also promotes the secretion of VEGF-A from fibroblasts and endothelial cells, and MMP-13 was suggested to directly and indirectly promote tumor invasion and angiogenesis, both in vitro and in vivo [38]. MMP-13 mediates collagenolysis-dependent angiogenesis in vivo [39]. Decreased tumor growth in MMP-13(-/-) mice was associated
with reduced blood vessel density [40], and a lack of MMP-13 reduced the vascular density of wound granulation tissue [41]. The diminished expression of MMP-13 in hypertrophic chondrocytes inhibited growth plate angiogenesis [42]. MMP-13 has recently been implicated in corneal vascularization [43]. In addition, MMP-13 contributes to experimental choroidal neovascularization [43] and acts as a stromal mediator in controlling persistent angiogenesis in skin carcinoma [44].

Bevacizumab is a well-known angiogenesis inhibitor that slows the growth of new blood vessels. This recombinant humanized monoclonal antibody binds to all types of human VEGF, thus preventing the interaction between VEGF and its receptors on the surface of endothelial cells [45]. Bevacizumab has been used to treat choroidal neovascularization, and more recently for diabetic macular edema [46–51]. Recent studies have demonstrated that subconjunctival bevacizumab injections are useful in the management of patients with recurrent pterygium [52–58].

Cyclosporine A (CsA) is one of the most promising immunosuppressive drugs and is widely used to prevent tissue rejection following organ transplantation [59]. CsA can be administered topically or by a subconjunctival injection to treat a variety of inflammatory disorders of the ocular surface [59–61]. CsA prevents the activation and nuclear translocation of cytoplasmic transcription factors that are required for T-helper cell activation and inflammatory cytokine production [62]. Importantly, topical application of CsA prevents pterygium recurrence [63–66]. A previous study suggested that CsA treatment of the residual conjunctiva after pterygium excision may block the activation and proliferation of pterygium fibroblasts [25]. Both in primary and recurrent pterygium, CsA is an effective inhibitor of fibroblast proliferation in culture [67]. It also inhibits endothelial cell proliferation and angiogenesis [68]. However, it is well known that CsA treatment can result in a number of potentially serious adverse drug reactions (ADRs). The risk of these ADRs increases with the CsA dosage and treatment time. Therefore, for safety, a low CsA concentration (0.05%) has been used for the treatment of many ocular conditions [69–74].

Although many MMPs were expressed in pterygium tissues, our study mainly focused the activities of MMP-3 and MMP-13 which may play an important role in the process of pterygium progression. Recently, we reported that CsA down-regulated MMP-3 and MMP-13 expression in cultured pterygium fibroblasts [75]. Interestingly, bevacizumab significantly reduced the expression of MMP-1 in cultured Tenon’s fibroblasts from primary and recurrent pterygium [76]. These studies prompted us to investigate whether bevacizumab down-regulates the expression of MMP-3 and MMP-13 in pterygium tissues in vivo, and decreases the migration of pterygium fibroblasts in vitro. Furthermore, we compared the inhibitory effects of CsA and bevacizumab on the regulation of MMP expression and migration of pterygium fibroblasts in vitro.

Materials and Methods

Ethics Statement

This present study was carried out with the approval of the Human Study ethics Committee at Cheil Eye Hospital, Daegu, Korea, and the specimens were handled in accordance with the tenets of the Declaration of Helsinki. Written informed consent was obtained from all participating patients.

Specimens from Patients

Specimens of pterygium tissue were collected from Korean patients (10 males and 10 females) during pterygium surgery. All specimens were taken from the head of the pterygium, which
had invaded the central cornea. Normal conjunctival tissues, to be used as a control, were collected from the conjunctiva of 6 patients (3 males and 3 females) during cataract surgery.

**Reagents**

Bevacizumab was purchased from Genentech Inc. (San Francisco, CA, USA) and CsA (0.05% Restasis®) was purchased from Allergan Inc. (Irvine, CA, USA). MMP-3 inhibitor VII and an MMP-13 inhibitor were purchased from Calbiochem (San Diego, CA, USA). The anti-MMP-3 antibody was purchased from Chemicon International Inc. (Temecula, CA, USA) and the anti-MMP-13 antibody was purchased from Abcam (Cambridge, MA, USA). Anti-β-actin was purchased from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA). 4',6-Diamidino-2-phenylindole (DAPI) and Prolong Gold were purchased from Invitrogen (Carlsbad, CA, USA).

**Preparation of Human Tissues and Cells**

Fibroblasts were obtained from pterygium and normal conjunctival specimens using the explant methods reported by Li et al. [24]. Immediately after excision, the tissue was placed in either Hanks' balanced salt solution or phosphate-buffered saline (PBS) containing 1% penicillin/streptomycin (Gibco BRL, Gaithersburg, MD, USA). The tissues were finely minced into 1-mm³ pieces and placed in six-well culture plates with 1 ml of Dulbecco's modified Eagle's medium (DMEM)/F12 (1:1 vol/vol) containing 10% fetal bovine serum (FBS; Gibco BRL, Gaithersburg, MD, USA), ITS (5 μg/ml insulin, 5 ng/ml selenium, 5 μg/ml human transferrin; Sigma), and 1% penicillin/streptomycin. Seeded tissues were incubated at 37°C in a humidified air atmosphere with 5% CO₂ and fed daily. When the cells began to form a monolayer, the tissue pieces were removed. When the conjunctival fibroblast cultures reached confluence, they were detached from the dishes using trypsin-EDTA and re-plated into new dishes at a ratio of 1:3. Primary human pterygium and conjunctival fibroblast cells (passages 4 and 5) were used in these experiments.

**Paraffin Embedding and Immunohistochemistry**

Pterygium and normal conjunctiva tissues were harvested in cold PBS, fixed in 4% paraformaldehyde (PFA) in PBS for 24 h at 4°C, and then washed twice in PBS. The samples were then dehydrated through an ethanol series, cleared by soaking in xylene, embedded in paraffin, and sectioned (5 μm) using a microtome RM 2125RT (Leica, Wetzlar, Germany). Slides containing paraffin sections were deparaffinized in xylene and rehydrated through an ethanol series, and endogenous peroxidase activity was inactivated by incubation in 0.3% H₂O₂ in methanol for 10 min. The sections were then rinsed in 0.1 M tris-buffered saline (TBS; pH 7.4) and boiled in citrate buffer (pH 6.0) containing 0.3% Tween-20 for 4 min. Finally, the sections were incubated with a blocking solution (5% normal goat serum and bovine serum albumin in TBS) at room temperature (RT) for 1 h, and subjected to indirect immunohistochemistry using an antibody against MMP-3 or MMP-13 for 1 h. For the negative control, the primary antibody was omitted and the slides were incubated with the blocking solution. Next, sections were incubated with the corresponding secondary antibodies conjugated with biotinylated anti-rabbit IgG and with Vectorstain ABS reagent (Vector Laboratories, CA, USA) for 1 h. Then, sections were incubated with a substrate from the VECTOR1 NovaRED substrate kit (Vector, Burlingame, CA), and counterstained with hematoxylin. The sections were dehydrated, cleared, and mounted with Permount (Fisher, Fair Lawn, NJ). Images were captured using a Zeiss microscope (Axio Vision 4; Carl Zeiss, Jena, Germany). Quantification of the immunohistochemical signal was performed by calculating the percentage of the stained area using ImageJ software (http://openwetware.org/wiki/Sean_Lauber:ImageJ_-_Threshold_Analysis).
Immunofluorescent Staining of Cells Migrating from Tissue Explants

When the cells began to form a monolayer, the tissue pieces were removed and fixed with 4% PFA in PBS (pH 7.4) at RT for 15 min. The fixed cells were permeabilized with 0.3% Triton-X for 10 min, and blocked overnight with 5% normal goat serum and BSA in TBS at 4°C. The cells were then incubated overnight with monoclonal antibodies against MMP-3 or MMP-13 (diluted 1:100) in 5% BSA, and washed three times in TBS. The cells were further incubated with the appropriate Alexa 488-conjugated secondary antibodies at RT for 1 h, and nuclei were counterstained with DAPI (1 μg/ml). The cells were washed three times with PBS and mounted prior to image capture using a Zeiss fluorescence microscope (Axio Vision 4; Carl Zeiss, Jena, Germany). The green fluorescence density was measured in a color histogram using the ImageJ software program.

Cell Migration and In Vitro Scratch Wound Assay

Passage 4 pterygium fibroblasts (3 × 10^5 cells/well) were seeded on 6-well plates in 2 ml DMEM/F12 (1:1 vol/vol) containing 10% FBS and allowed to adhere for 24 h. Cells were then washed and incubated with serum-free medium. At this time, a scratch was made through the center region of the confluent sheet using a yellow pipette tip; suspended and detached cells were then washed out with the serum-free medium. Indentations were made within the wound area to establish points of reference [77]. The cells were then exposed to MMP-3 inhibitor VII (1 μM), an MMP-13 inhibitor (1 μM), or bevacizumab (1 μg/ml) in serum-free DMEM-F12 medium, and maintained for 24 or 48 h without a medium change. Cells were exposed to CsA (1 or 100 μg/ml) for 3 or 10 min prior to incubation with fresh serum-free medium, with or without bevacizumab, for 24 or 48 h. Images were captured at the same position within the wound region and the cell migration rate was determined using ImageJ.

Measurement of Cell Migration from Tissue Explants

When cells began to migrate, they were exposed to MMP-3 inhibitor VII, an MMP-13 inhibitor, bevacizumab, and/or CsA. Cell migration was captured daily by phase contrast microscope for three days.

Subconjunctival Administration of Bevacizumab

This procedure was conducted at the Cheil Eye Hospital in Daegu, on patients with primary pterygium. One surgeon (Y.J. Park) performed all of the surgeries using previously described surgical techniques [78, 79]. The eyes were anesthetized with topical proparacaine hydrochloride drops (Alcaine, Alcon) and visualized under a microscope in order to administer a subconjunctival injection of 2.5 mg/0.1 ml bevacizumab on the pterygium body using a 1-ml syringe with a 30-gauge needle [78, 79]. After the subconjunctival injection of bevacizumab, the patients were treated with topical levofloxacin (Cravit, Santen Pharmaceutical, Osaka, Japan) eye drops 4 times/day for 1 week. Then, the pterygium surgical technique reported by Kim at al. [80] was performed on each patient. After the tissue was harvested, it was fixed with 4% PFA.

Western Blot Analysis

For lysate preparation, tissues or cultured cells were washed twice with PBS and then placed in ice-cold radioimmunoprecipitation assay (RIPA) buffer containing a protease inhibitor cocktail (Sigma, St. Louis, MO). The lysate protein concentration was determined using a bicinchoninic acid assay kit. Western blot analysis was performed using standard techniques. Equal amounts of lysate protein (30 μg) in the RIPA buffer were separated by 8% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis under reducing conditions, and the proteins were electrophoretically transferred to nitrocellulose membranes. The membranes were blocked in 5% non-fat dried milk in TBS containing 0.1% Tween-20 (TBS-T) for 1 h, and then incubated overnight at 4°C with primary polyclonal antibodies raised against MMP-3, MMP-13, or β-actin; these were all diluted in TBS-T containing 5% dried milk. The primary antibodies were detected by incubation with horseradish peroxidase-conjugated secondary antibodies for a further 1 h. Specific antibody binding was visualized using an enhanced chemiluminescence detection kit (ELPIS Biotech, Korea) and X-ray film exposure. The presented data were representative of at least three independent experiments. Densitometric analyses were conducted using Image J software.

Statistical Analysis
Each experiment was repeated three or more times. Data were evaluated by one-way analysis of variance (ANOVA) and Turkey’s test or by two-way ANOVA. The analyses were performed using GraphPad PRISM software (GraphPad PRISM software Inc., Version 5.02, CA, USA). Results are expressed as the mean± the standard error of the mean, and P values of < 0.05 were considered statistically significant.

Results
Immunohistochemical Localization of MMP-3 and MMP-13 in Human Conjunctival and Pterygium Tissues
To examine the association of pterygium with MMP-3 and MMP-13 protein expression, immunohistochemistry was performed on normal conjunctival and pterygium tissues (Fig 1). In the normal conjunctiva, the epithelium regularly consisted of 5-6 cell layers (Fig 1A). In contrast, irregular and hyperplasic multilayers of epithelium were seen in the pterygium groups (Fig 1B). We identified numerous surface epithelium goblet cells (\(^*\)), grouped as intraepithelial glands with foamy cytoplasm (Fig 1B). In the pterygium tissue, MMP-3 and MMP-13 expression levels were significantly stronger than those observed in normal conjunctival tissues. The stained areas were 41.37-54.77% (MMP-3) and 54.81-71.90% (MMP-13) larger in the pterygium tissue than in the normal conjunctival tissue (Fig 1C). Interestingly, expression of both MMP-3 and MMP-13 proteins was detected in the epithelium and stroma of the pterygium tissue, but these were weakly expressed in normal conjunctival tissue (Fig 1A). Notably, as compared to the MMP-3 staining pattern, more intense MMP-13 staining was detected in the superficial epithelial layer of the pterygium tissue.

Correlation Between MMP-3 and MMP-13 Expression and Pterygium Fibroblast Migration
Based on the immunohistochemical data (Fig 1), we examined whether fibroblasts migrating from the pterygium explant culture expressed high levels of MMP-3 and MMP-13. Fig 2 shows that normal conjunctiva fibroblasts had started to migrate out from the cultured specimens by day 3. Both conjunctiva and pterygium specimens were removed just before staining (dotted white line). Immunofluorescence staining of conjunctiva tissue identified few migratory cells that expressed MMP-3 (Fig 2A) and MMP-13 (Fig 2B). On the other hand, many more migratory cells from the pterygium specimen expressed MMP-3 and MMP-13 (direction to dotted yellow arrow) (Fig 2). In addition, DAPI staining confirmed that many migratory cells had grown out from the edge of the pterygium tissue. As expected, fewer cells remained in the region that the pterygium tissue had been removed from inside the dotted white lines. In contrast, many cells were not migratory and thus remained in the region that the conjunctiva tissue had been
MMP Activities and Pterygium Progression

A
Conjunctiva tissue

MMP-3

MMP-13

Negative control

B
Pterygium tissue

MMP-3

MMP-13

Negative control

C

Conjunctiva tissue  Pterygium tissue

DAB Positive staining (% of Total Area)

MMP-3  MMP-13

*  **
removed from just before staining (Fig 2). To quantify the number of migrating fibroblasts expressing both MMP-3 and MMP-13 proteins, we created a bar graph to summarize the relevant data. The resultant pixel value was 1.5-2-fold higher for the pterygium tissue explant than for the normal conjunctiva tissue (Fig 2C).

Effects of MMP-3 or MMP-13 Inhibition on Pterygium Fibroblast Migration

The fibroblasts migrating from pterygium tissue explants produced both MMP-3 and MMP-13 proteins (Fig 2), and we therefore examined whether inhibition of either of these activities affected fibroblast outgrowth from the explanted pterygium for 2 days (0 h) (Fig 3). Thereafter, pterygium explants were cultured in serum-free medium in the presence of MMP inhibitors for 24 and 48 h. As the culture time increased, the number of fibroblasts that grew out from the tissue edge gradually increased under non-treated control culture conditions (Fig 3A). On the other hand, treatment with either an MMP-3 or MMP-13 inhibitor greatly inhibited fibroblast outgrowth from the tissue edge over time. Quantification of fibroblast outgrowth from the tissue edge also found a significant reduction in the presence of an MMP-3 or MMP-13 inhibitor (Fig 3B). Taken together, these data indicate that fibroblast outgrowth from the pterygium tissue edge was mediated, at least in part, by MMP-3 and MMP-13.

Effects of MMP-3 and MMP-13 Inhibition on Pterygium Fibroblast Migration into a Scratch Wound

A pure pterygium fibroblast culture was established from the explant-cultured pterygium tissue, as shown in a previous study [77]. In the present study, a scratch wound assay was performed to evaluate the effects of MMP-3 and MMP-13 inhibition on the migration of pterygium-derived fibroblasts. The scratch wound assay clearly demonstrated that an inhibitor of MMP-3 (1 μM) or MMP-13 (1 μM) retarded coverage of the uniform width of the wound area (Fig 4A). After 24 h, many cells had migrated into the wound region of the control culture, but only a few cells had migrated into the wound region in inhibitor-exposed cultures. After 48 h, control cultured cells had covered the wound area, whereas wound closure was significantly reduced in the cells exposed to an MMP-3 or MMP-13 inhibitor (Fig 4A). There were statistically significant differences between the control group and the treated groups (Fig 4B). Compared to the control culture, cell migration was 52.38% (MMP-3 inhibitor) and 51.87% (MMP-13 inhibitor) lower after 24 h, and 50.35% (MMP-3 inhibitor) and 44.72% (MMP-13 inhibitor) lower after 48 h in culture. Taken together, these data suggest that the migration of pterygium fibroblasts occurs in an MMP-dependent manner.

Reduction of MMP-3 and MMP-13 Protein Levels Following Subconjunctival Bevacizumab Injection

Changes in the expression levels of both MMP-3 and MMP-13 proteins were examined. Following subconjunctival administration of bevacizumab to pterygium patients for 7 days,
immunohistochemistry was performed using excised pterygium tissues (Fig 5A). Interestingly, expression of both MMP-3 and MMP-13 proteins was significantly lower in patients treated with bevacizumab. There was no detectable expression of MMP-3 and MMP-13 proteins in the negative control sections (Fig 5A, middle panels). Next, the expression levels of MMP-3 and MMP-13 proteins were measured by western blot analysis (Fig 5B) using lysates of 3 normal conjunctiva tissues from 6 patients and of 4 pterygium tissues from 20 patients, as described in the Materials and Methods section. Higher levels of both proteins were clearly detected in pterygium tissues, as compared to those in normal conjunctiva tissues. This analysis also confirmed that the MMP-3 and MMP-13 protein expression levels decreased markedly following bevacizumab administration for 7 days (Fig 5B). These results indicate that bevacizumab mediates the down-regulation of both proteins in the pterygium tissue. There were also statistically significant differences in the expression levels of both proteins in the conjunctiva, pterygium, and bevacizumab-treated pterygium tissues (Fig 5C). Following normalization to β-actin expression, MMP-3 and MMP-13 levels increased by 1.7-fold and 3.02-fold (respectively) in pterygium tissue, as compared to their levels in conjunctiva tissue. In contrast, the intensity of both protein bands was significantly reduced in the pterygium tissues treated with bevacizumab (MMP-3, 0.13-fold; MMP-13, 1.27-fold), as compared to pterygium tissue from untreated patients (Fig 5C). These results suggest that bevacizumab exerts an important effect on cell migration that may be mediated, in part, by inhibition of MMP-3 and MMP-13 expression.

**Inhibitory Effects of Bevacizumab on MMP Expression and Pterygium Fibroblast Migration into a Scratch Wound**

Fig 6 shows the effects of bevacizumab on cultured confluent pterygium fibroblast migration following a scratch wound, in relation to MMP-3 and MMP-13 expression. Phase-contrast microscopy (Fig 6A) of the control culture 24 h after the scratch wound (a) showed that many cells had migrated into the wound region from the wound edge; however, there were very few or no cells in the wound region of the bevacizumab-treated group (b). By 48 h, the control wound region was completely covered with fibroblasts (c), while few cells were observed in the wound region of the bevacizumab-treated group (d). Western blot analysis also showed that both MMP-3 and MMP-13 expression levels markedly decreased in the bevacizumab-treated cultures at 24 h, as compared to the high levels of both proteins observed in the control cultures (Fig 6B). The differences in MMP-3 (4.19-fold) and MMP-13 (3.66-fold) protein levels between the control and bevacizumab-treated cells were statistically significant ($P < 0.05$; Fig 6C).

**Combined Inhibitory Effect of Bevacizumab and CsA on Pterygium Fibroblast MMP Expression and Migration into a Scratch Wound**

A previous study showed that CsA (0.05%) inhibited the proliferation of pterygium-derived fibroblasts in culture [81]. The present study therefore investigated whether CsA inhibited the migration of pterygium fibroblasts or altered MMP expression following a scratch wound. Immediately after the scratch wound was made through the middle of the confluent cultured
pterygium fibroblasts, cells were pretreated with CsA (1 μg/ml or 100 μg/ml) for 3 or 10 min. These cells were then cultured in the presence or absence of bevacizumab (1 μg/ml) for 24 h (Fig 7). Interestingly, although pretreatment with CsA inhibited cell migration, as compared to control cultures, there was no difference in cell migration, regardless of treatment time or concentrations of CsA (Fig 7A). In addition, we observed that CsA pretreatment inhibited cell migration to a greater extent than bevacizumab treatment alone (Fig 7B). Furthermore, we examined the effects of CsA on MMP-3 and MMP-13 expression in pterygium fibroblasts 24 h after the scratch wound was made (Fig 7C). This western blot analysis showed that levels of MMP-3 and MMP-13 proteins were much lower in the CsA-pretreated (100 μg/ml) groups (3 and 10 min) than in the control cultures (Fig 7C and 7D). Furthermore, cells that were CsA-pretreated and exposed to bevacizumab showed slightly lower expression levels of both MMPs. Taken together, these results suggest that CsA may inhibit the migration of pterygium fibroblasts by down-regulating both MMP-3 and MMP-13.

Effects of Bevacizumab and CsA on Fibroblast Migration from Pterygium Explants

Next, we examined whether bevacizumab and CsA affected fibroblast outgrowth from cultured pterygium tissue explants over 48 h (Fig 8). In the control cultures, many fibroblasts migrated out a long distance from the pterygium explant tissue. The distance migrated by the cells from the edge of the pterygium explants was markedly reduced by treatment with either bevacizumab (1 μg/ml) or pretreatment with CsA (100 μg/ml) for 3 min, as compared to control cultures. Interestingly, a greater inhibition of the migration distance was observed in the CsA-pretreated group than in the bevacizumab-treated group. Moreover, we found that the inhibitory effect of combined CsA pretreatment and bevacizumab was higher than that of the individual treatments (Fig 8A). Quantification of the migration distance demonstrated that the rate of cell migration was significantly decreased by CsA pretreatment, with or without bevacizumab (Fig 8B). Together, these data suggest that signaling events triggered by CsA or bevacizumab can play an important role in fibroblast migration.

Discussion

It is well known that members of the MMP family of enzymes mediate cell migration by influencing ECM proteolysis and remodeling during developmental and pathogenic processes. Previous studies have demonstrated that a pterygium arises when altered limbal basal epithelial cells (pterygium cells) expressing multiple types of MMPs move onto BL and bring about the dissolution of this layer [4, 5, 26]. Activated and altered fibroblasts at the head of the pterygium primarily express MMP-1 [22]. The levels of MMPs in the pterygium and in its fibroblasts are closely related. Pterygium progression is characterized by the development of angiogenesis and the proliferation of fibrovascular tissue [82]. In the present study, we have focused on the involvement of MMP-3 and MMP-13 in pterygium pathogenesis, and identified high levels of expression of both of these MMPs in migrating pterygium fibroblasts (Fig 2). Importantly, exposure to potent inhibitors of MMP-3 or MMP-13 activity suppressed the migration of cells...
Fig 4. Inhibition of MMP-3 or MMP-13 activity reduced pterygium-derived fibroblast migration. Pterygium fibroblasts were treated with an MMP-3 (1 μM) or MMP-13 (1 μM) inhibitor in serum-free medium, directly after the scratch wound. (A) Representative phase contrast microscopy images taken at 24 h and 48 h after a single uniform-width scratch wound of confluent pterygium fibroblasts. Dashed lines indicate the precise location of the scratch wound. Scale bar: 50 μm. (B) Pooled quantitative data of pterygium-derived fibroblast migration. Data were summarized as the mean ± standard deviation of 3 separate experiments. ***P < 0.001 vs control.

doi:10.1371/journal.pone.0169675.g004
Taken together, these findings suggest that MMP-3 and MMP-13 activities are both required for the migration of pterygium fibroblasts in the pathogenesis of pterygia. In addition, we demonstrated that combined treatment with bevacizumab and/or CsA down-regulated both MMP-3 and MMP-13 expression and greatly decreased pterygium fibroblast migration, confirming that these activities are necessary for this process.

Possible Roles of MMP-3 in Pterygium Progression

Types I, II, III, and IV collagens make up a large component of the ECM material in pterygia [83, 84]. MMP-1 can degrade native fibrillar collagen types I, II, III, IX, and XI [85]. MMP-3 has a broad substrate specificity that includes casein, proteoglycans, fibronectin, elastin, and
Laminin, as well as collagen types III, IV, V, IX, and X [24]. Pterygium fibroblasts express mainly MMP-1 in response to cytokines and UV irradiation, as well as some MMP-3, but almost none of the other MMPs [22, 84]. Other recent studies have shown that MMP-3 levels are elevated in pterygia [5, 17]. Fibroblasts in pterygia, in areas of elastotic degradation, were mainly immunostained for both MMPs [22]. In areas of BL dissolution, as indicated by immunostaining of MMP-1 and MMP-3, pterygium fibroblasts invading the cornea are likely to play an important role in helping to dissolve BL [18, 24]. Elevated MMP-1 and -3 expression and activities were also detected in pterygium head fibroblasts [5, 24]. Following exposure to inflammatory cytokines, expression of MMP-1, MMP-2, and MMP-3 was up-regulated in cultured pterygia fibroblasts [24, 25]. MMP-3 may play a key role in ECM remodeling because it can activate other latent forms of MMPs including MMP-1, MMP-7, and MMP-9, [5, 86]. Taken together with the high levels of MMP-3 expression observed in the present study, these findings indicate that MMP-3 is a potential candidate molecule for involvement in the pathogenesis and progression of pterygium.

Possible Roles of MMP-13 in Pterygium Progression

A previous study demonstrated the immunohistochemical localization of collagen types I, II, III, and IV in the pterygium [83]. The stromata of pterygium and normal conjunctival
tissues contain collagen types I, II, and III [83]. The expression of MMP-13 appears to be relatively restricted and confined to a few normal tissues [87]. MMP-13 can readily cleave the triple helical domain of native fibrillar collagens I, II, and III, as well as other ECM molecules [3]. A previous study reported that the staining intensity of MMP-13 was greater in pterygium epithelial cells than in pterygium fibroblasts for 24 h. Data represent the mean ± standard deviation of 3 separate experiments. ***P < 0.001 vs CsA. On the other hand, consistent with our immunohistochemical data shown in Fig 1, another study identified strong MMP-13 expression over the entire pterygium stroma and epithelium [3]. The expression of MMP-13 was also detected at the leading edge of pterygia [26]. Variation in the expression of MMPs may explain the differences in the growth of pterygia seen clinically [17]. A characteristic feature of pterygia is the loss of BL, presumably due to over-expression of MMPs [26]. MMP-13 was stained intensely in the basal and columnar epithelium, particularly in the regions of fragmented BL, adjacent to pterygium fibroblasts [26]. Therefore, we suggest that MMP-13 expressed by pterygium tissues may induce collagen II and III remodeling in pterygium stroma. Furthermore, our results suggest that pterygium recurrence in vivo results from uncontrolled degradation of the ECM caused by an excess of MMP-13 in pterygium tissues.

Fig 7. Combined Bevacizumab- and CsA-induced inhibition of scratch wound pterygium fibroblast migration and down-regulation of MMP-3 and MMP-13 expression. (A) Phase contrast microscopy of pterygium fibroblasts 24 h after scratch wounding. Cell migration in the scratched area was greatly reduced in the presence of CsA and/or bevacizumab. Dashed lines indicate the precise location of the scratch wound. White scale bar: 50 μm. (B) The migration rates were quantified in cells pretreated with CsA for 3 min or 10 min prior to incubation with bevacizumab for 24 h. Data represent the mean ± standard deviation of 3 separate experiments. ***P < 0.001 vs CsA. (C) Western blot analysis showed that expression of both MMPs was markedly reduced by combined bevacizumab and CsA treatment. (D) Band densities were analyzed using ImageJ, relative to the relevant β-actin band. Data represent the mean ± standard deviation of 3 separate experiments. ***P < 0.001 vs control; *P < 0.05, ***P < 0.001 vs CsA; †P < 0.01, ††P < 0.001 vs bevacizumab. doi:10.1371/journal.pone.0169675.g007
Inhibition of Pterygium Fibroblast Migration by Bevacizumab-induced Down-regulation of MMP-3 and MMP-13

MMP-3 has been clearly implicated in angiogenesis because it generates angiotatin, whereas its inhibitor inhibits angiogenic responses [32–34]. In addition, MMP-3 has been shown to induce vascular endothelial cell growth or migration [5, 88]. MMP-13 also mediates collagenolysis-dependent angiogenesis in vivo [39]. MMP-13 acts as a stromal mediator in controlling persistent angiogenesis in skin carcinoma [44]. MMP-13 also promotes the secretion of VEGF-A from fibroblasts and endothelial cells, and it is suggested that MMP-13 may directly and indirectly promote tumor invasion and angiogenesis both in vitro and in vivo [38]. In addition, MMP-13 has been implicated in corneal vascularization [43]. On the other hand, diminished expression of MMP-13 in hypertrophic chondrocytes inhibits growth-plate angiogenesis [42]. Lack of MMP-13 reduces the vascular density of wound granulation tissue in mouse skin [41]. Importantly, the present study found that treatment with MMP-3 or MMP-13 inhibitors reduced the migration of fibroblasts from cultured pterygium tissues and into a scrape wound (Figs 3 and 4).

VEGF is known to have a role in angiogenesis and is markedly elevated in pterygia, as compared with normal conjunctival samples [28–31]. In addition, VEGF is secreted at high levels by
human pterygium fibroblasts [89]. Bevacizumab (Avastin) is an angiogenesis inhibitor that slows the growth of new blood vessels. Avastin treatment decreased human pterygium fibroblast migration and invasion [89]. Many previous studies have shown that subconjunctival bevacizumab injections are useful in the management of patients with recurrent pterygium, without significant local or systemic adverse effects. Bevacizumab has been shown to decrease both angiogenesis and pterygium recurrence [57, 90–94]. The present in vivo and in vitro bevacizumab results (Figs 5, 6, 7 and 8) indicate that there was a strong correlation between the inhibition of MMP-3 and MMP-13 expression by bevacizumab and the inhibition of pterygium fibroblast migration. Interestingly, a previous study showed that increased levels of MMPs promoted dissolution of the BL and promoted both angiogenesis and pterygium invasion of the cornea [27]. To date, there are no MMP studies that relate to pterygium recurrence. Although the detailed mechanisms involved in bevacizumab-mediated inhibition of MMP-3 and MMP-13 expression and pterygium fibroblast migration are currently unknown, the present study suggests that bevacizumab could make an important contribution to the management of pterygia. Further study will be necessary in order to elucidate the mechanism underlying this effect.

Combined Effects of CsA and Bevacizumab on MMP-3, MMP-13, and Pterygium Fibroblast Migration

The first-line treatment for pterygium is surgical excision, but recurrence is the most common complication [63]. CsA, an anti-inflammatory agent, has been administered topically to treat a variety of inflammatory disorders of the ocular surface [60]. Postoperative application of topical 0.05% CsA can provide effective prevention of recurrence after primary pterygium surgery [64, 65, 95]. To the best of our knowledge, no previous studies have examined the relationship between MMP-3 and MMP-13 expression by pterygium explants and cultured pterygium-derived fibroblasts, and treatment using bevacizumab and/or CsA. Interestingly, similar to the bevacizumab effects, CsA produced a significant reduction in MMP-3 and MMP-13 expression and in pterygium fibroblast migration (Figs 7 and 8). Importantly, combined CsA and bevacizumab produced a larger inhibition of MMP-3 and MMP-13 expression and of pterygium fibroblast migration, as compared to treatment with bevacizumab or CsA alone (Figs 7 and 8). Therefore, we suggest that bevacizumab and CsA produced synergistic down-regulation of MMP expression and pterygium cell migration. UV-inducible cytokines generated by the pterygium epithelium, such as interleukins and tumor necrosis factor (TNF)-α, may contribute to the initiation of neovascularization and chronic inflammation during pterygium formation [84, 96]. Interleukin-6 has been shown to increase angiogenesis via VEGF induction [97]. Although previous studies suggest that CsA prevents the synthesis and secretion of interleukins [98, 99] and TNF-α [100], and blocks VEGF-induced angiogenesis [99, 101, 102], the mechanisms involved in CsA-mediated inhibition of MMP expression and pterygium fibroblast migration have not been completely elucidated. However, the present data suggest that increased expression of MMP-3 and MMP-13 by pterygium fibroblasts may be involved in the pathogenesis of pterygium, and combination treatment with bevacizumab and CsA therefore represents a potential therapy for pterygium recurrence.

In summary, our study demonstrated for the first time that the combined actions of CsA and bevacizumab produced stronger inhibitory effects on MMP expression and in vitro pterygium fibroblast migration than either intervention alone. Therefore, the combined application of CsA and bevacizumab could provide a useful alternative approach to the clinical management of pterygium recurrence. Further studies will be necessary to understand the precise molecular mechanisms underlying these effects.
Supporting Information

S1 Fig. Inhibition of cell migration by treatment of VEGF inhibitors (bevacizumab, aflibercept and ranibizumab) in scratch wound pterygium fibroblasts. Effects of bevacizumab (1 μg/ml), aflibercept (a recombinant fusion protein which binds all VEGF-A isoforms, 1 μg/ml), and ranibizumab (a monoclonal antibody fragment (Fab) created from the same parent mouse antibody as bevacizumab, 1 μg/ml) on cell migration were determined by using a scratch-wound healing migration assay. (A) By phase-contrast microscopy, compared to control cultured cells, cell migration was markedly blocked in pterygium fibroblast cells by treatment with bevacizumab, aflibercept, and ranibizumab at 24 h and 48 h. Dashed lines indicate the precise location of the scratch wound. (B) The quantification of migration length and migrated cell numbers. Note that compared to control culture, cell migration was significantly inhibited by all treatment groups. As expected, migrated cell numbers were increased in control cultures for 24 h and 48 h, compared to all treatment groups. Data were summarized as mean ± SD from 3 separated experiments. ***P < 0.001 vs control. (TIF)

Acknowledgments

This study was supported by the 2012 Cheil-namnyung Foundation Research Fund. In addition, this work was supported by the Grant K16281, awarded to the Korea Institute of Oriental Medicine (KIOM) from the Ministry of Science, ICT and Future Planning (MSIP), Republic of Korea. This research was supported by the Basic Science Research Program, through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (2015R1D1A1A01060777).

Author Contributions

Conceptualization: YHK JCJ YJP.
Data curation: YHK JCJ.
Funding acquisition: KWL JYM JCJ.
Investigation: YHK SIG SBP YIK.
Methodology: YHK JCJ YJP.
Project administration: YJP.
Resources: JCJ YJP.
Software: YHK SIG.
Supervision: YJP.
Validation: YHK SIG.
Visualization: YHK JCJ.
Writing – original draft: YHK JCJ.
Writing – review & editing: YHK JCJ.

References

1. Tsai YY, Chiang CC, Yeh KT, Lee H, Cheng YW. Effect of TIMP-1 and MMP in pterygium invasion. Invest Ophthalmol Vis Sci. 2010; 51(7):3462–7. doi: 10.1167/ios.09-4921 PMID: 20207965
2. Dushku N, Reid TW. Immunohistochemical evidence that human pterygia originate from an invasion of vimentin-expressing altered limbal epithelial basal cells. Curr Eye Res. 1994; 13(7):473–81. PMID: 7924411

3. Naib-Majani W, Eltohami I, Wemert N, Watts W, Tschesche H, Pleyer U, et al. Distribution of extracellular matrix proteins in pterygia: an immunohistochemical study. Graefes Arch Clin Exp Ophthalmol. 2004; 242(4):332–8. doi: 10.1007/s00417-003-0846-y PMID: 14749931

4. Reid TW, Dushku N. What a study of pterygia teaches us about the cornea? Molecular mechanisms of formation. Eye Contact Lens. 2010; 36(5):290–5. doi: 10.1097/ICL.0b013e3181eea8fe PMID: 20724855

5. Seet LF, Tong L, Su R, Wong TT. Involvement of SPARC and MMP-3 in the pathogenesis of human pterygium. Invest Ophthalmol Vis Sci. 2012; 53(2):587–95. doi: 10.1167/iovs.11-7941 PMID: 22222271

6. Chui J, Di Girolamo N, Wakefield D, Coroneo MT. The pathogenesis of pterygium: current concepts and their therapeutic implications. The ocular surface. 2008; 6(1):24–43. PMID: 18264653

7. Coroneo MT. Pterygium as an early indicator of ultraviolet insolation: a hypothesis. The British journal of ophthalmology. 1993; 77(11):734–9. PMID: 8280691

8. Coroneo MT, Di Girolamo N, Wakefield D. The pathogenesis of pterygia. Current opinion in ophthalmology. 1999; 10(4):282–8. PMID: 10621537

9. Hilgers JH. Pterygium: its incidence, heredity and etiology. American journal of ophthalmology. 1960; 50:635–44. PMID: 13714649

10. Karai I, Horiguchi S. Pterygium in welders. The British journal of ophthalmology. 1984; 68(5):347–9. PMID: 6712915

11. Threlfall TJ, English DR. Sun exposure and pterygium of the eye: a dose-response curve. American journal of ophthalmology. 1999; 128(3):280–7. PMID: 10511020

12. Massova I, Kotara LP, Mobashery S. Structural insight into the binding motifs for the calcium ion and the non-catalytic zinc in matrix metalloproteinases. Bioorg Med Chem Lett. 1998; 8(7):853–8. PMID: 9871554

13. Nagase H, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem. 1999; 274(31):21491–4. PMID: 10419448

14. Bai H, Teng Y, Wong L, Jhanji V, Pang CP, Yam GH. Proliferative and migratory aptitude in pterygium. Histochem Cell Biol. 2010; 134(5):527–35. doi: 10.1007/s00418-010-0751-5 PMID: 20938674

15. Cameron ME. Histology of pterygium: an electron microscopic study. The British journal of ophthalmology. 1983; 67(9):604–8. PubMed Central PMCID: PMCPMC1040139. PMID: 6882718

16. An MX, Wu KL, Lin SC. Detection and comparison of matrix metalloproteinase in primary and recurrent pterygium fibroblasts. Int J Ophthalmol. 2011; 4(4):353–6. PubMed Central PMCID: PMCPMC3340879. doi: 10.3980/j.issn.2222-3959.2011.04.05 PMID: 22553679

17. Bradley JC, Yang W, Bradley RH, Reid TW, Schwab IR. The science of pterygia. The British journal of ophthalmology. 2010; 94(7):815–20. doi: 10.1136/bjo.2008.151852 PMID: 19515643

18. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nature reviews. 2002; 2(3):161–74. doi: 10.1038/nrc745 PMID: 1190893

19. Li DQ, Mellor D, Liu Y, Tseng SC. Overexpression of MMP-1 and MMP-3 by cultured conjunctivochalasia fibroblasts. Invest Ophthalmol Vis Sci. 2000; 41(2):404–10. PMID: 10607496

20. Di Girolamo N, Coroneo MT, Wakefield D. Active matrilysin (MMP-7) in human pterygia: potential role in angiogenesis. Invest Ophthalmol Vis Sci. 2001; 42(9):1963–8. PMID: 11481258

21. Di Girolamo N, Wakefield D. In vitro and in vivo expression of interstitial collagenase/MMP-1 by human mast cells. Dev Immunol. 2000; 7(2–4):131–42. PubMed Central PMCID: PMCPMC2276052. doi: 10.1155/2000/82708 PMID: 11097207

22. Dushku N, John MK, Schultz GS, Reid TW. Pterygium pathogenesis: corneal invasion by matrix metalloproteinase expressing altered limbal epithelial basal cells. Arch Ophthalmol. 2001; 119(5):695–706. PMID: 11346397

23. Girolamo F, Virgintino D, Errede M, Capobianco C, Bernardini N, Bertossi M, et al. Involvement of metalloproteinase-2 in the development of human brain microvessels. Histochem Cell Biol. 2004; 122(3):261–70. doi: 10.1007/s00418-004-0705-x PMID: 15375663

24. Li DQ, Lee SB, Gunja-Smith Z, Liu Y, Solomon A, Mellor D, et al. Overexpression of collagenase (MMP-1) and stromelysin (MMP-3) by pterygium head fibroblasts. Arch Ophthalmol. 2001; 119(1):71–80. PMID: 11146729
25. Solomon A, Li DQ, Lee SB, Tseng SC. Regulation of collagenase, stromelysin, and urokinase-type plasminogen activator in primary pterygium body fibroblasts by inflammatory cytokines. Invest Ophthalmol Vis Sci. 2000; 41(8):2154–63. PMID: 10892857

26. Di Girolamo N, Wakefield D, Coroneo MT. Differential expression of matrix metalloproteinases and their tissue inhibitors at the advancing pterygium head. Invest Ophthalmol Vis Sci. 2000; 41(13):4142–9. PMID: 11095607

27. Yang SF, Lin CY, Yang PY, Chao SC, Ye YZ, Hu DN. Increased expression of gelatinase (MMP-2 and MMP-9) in pterygia and pterygium fibroblasts with disease progression and activation of protein kinase C. Invest Ophthalmol Vis Sci. 2009; 50(10):4588–96. doi: 10.1167/iovs.08-3147 PMID: 19420332

28. Gebhardt M, Mentlein R, Schaudig U, Pufe T, Recker K, Nolle B, et al. Differential expression of vascular endothelial growth factor implies the limbal origin of pterygia. Ophthalmology. 2005; 112(6):1023–30. doi: 10.1016/j.ophtha.2005.01.023 PMID: 15885787

29. Jin J, Guan M, Sima J, Gao G, Zhang M, Liu Z, et al. Decreased pigment epithelium-derived factor and increased vascular endothelial growth factor levels in pterygia. Cornea. 2003; 22(5):473–7. PMID: 12827055

30. Lee DH, Cho HJ, Kim JT, Choi JS, Joo CK. Expression of vascular endothelial growth factor and inducible nitric oxide synthase in pterygia. Cornea. 2001; 20(7):738–42. PMID: 11588427

31. Marcovich AL, Morad Y, Sandbank J, Huszar M, Rosner M, Pollack A, et al. Angiogenesis in pterygium: morphometric and immunohistochemical study. Curr Eye Res. 2002; 25(1):17–22. PMID: 12518239

32. Cornelius LA, Nehring LC, Harding E, Bolanowski M, Welgus HG, Kobayashi DK, et al. Matrix metalloproteinases generate angiotatin: effects on neovascularization. J Immunol. 1998; 161(12):6845–52. PMID: 9862716

33. Stetler-Stevenson WG. Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. J Clin Invest. 1999; 103(9):1237–41. PubMed Central PMCID: PMCPMC408361. doi: 10.1172/JCI96870 PMID: 10225966

34. Sahin H, Tholema N, Petersen W, Raschke MJ, Stange R. Impaired biomechanical properties correlate with neoangiogenesis as well as VEGF and MMP-3 expression during rat patellar tendon healing. J Orthop Res. 2012; 30(12):1952–7. doi: 10.1002/jor.22147 PMID: 22615070

35. Nagase H. Activation mechanisms of matrix metalloproteinases. Biol Chem. 1997; 378(3–4):151–60. PMID: 9165065

36. Lijnren HR. Plasmin and matrix metalloproteinases in vascular remodeling. Thromb Haemost. 2001; 86(1):324–33. PMID: 11487021

37. Toriseva M, Laato M, Carpen O, Ruohon ST, Savontaus E, Inada M, et al. MMP-13 regulates growth of wound granulation tissue and modulates gene expression signatures involved in inflammation, proteolysis, and cell viability. PLoS One. 2012; 7(8):e42596. PubMed Central PMCID: PMCPMC3413640. doi: 10.1371/journal.pone.0042596 PMID: 22880047

38. Kudo Y, Iizuka S, Yoshida M, Tsunematsu T, Kondo T, Subarnbhe saj A, et al. Matrix metalloprotei-nase-13 (MMP-13) directly and indirectly promotes tumor angiogenesis. J Biol Chem. 2012; 287(46):38716–28. PubMed Central PMCID: PMCPMC3493915. doi: 10.1074/jbc.M112.373159 PMID: 22992737

39. Zijlstra A, Aimes RT, Zhu D, Regazzoni K, Kupriyanova T, Seandel M, et al. Collagenolysis-dependent angiogenesis mediated by matrix metalloproteinase-13 (collagenase-3). J Biol Chem. 2004; 279(26):27633–45. doi: 10.1074/jbc.M313617200 PMID: 15066996

40. Zigrino P, Kuhn I, Bauerle T, Zamek J, Fox JW, Neumann S, et al. Stromal expression of MMP-13 is required for melanoma invasion and metastasis. J Invest Dermatol. 2009; 129(11):2686–93. doi: 10.1038/jid.2009.130 PMID: 19516266

41. Hattori N, Mochizuki S, Kishi K, Nakajima T, D’Armiento J, et al. MMP-13 plays a role in keratinocyte migration, angiogenesis, and contraction in mouse skin wound healing. Am J Pathol. 2009; 175(2):533–46. PubMed Central PMCID: PMCPMC2716954. doi: 10.2353/apath.2009.081080 PMID: 19590036

42. Nagai H, Aoki M. Inhibition of growth plate angiogenesis and endochondral ossification with diminished expression of MMP-13 in hypertrophic chondrocytes in FGF-2-treated rats. J Bone Miner Metab. 2002; 20(3):142–7. doi: 10.1007/s0077402000020 PMID: 11984696

43. Lecomte J, Louis K, Debray B, Blacher S, Lambert V, Bekaert S, et al. Bone marrow-derived mesenchymal cells and MMP13 contribute to experimental choroidal neovascularization. Cell Mol Life Sci. 2011; 68(4):677–86. doi: 10.1007/s00018-010-0476-6 PMID: 20700625
44. Lederle W, Hartenstein B, Meides A, Kunzelmann H, Werb Z, Angel P, et al. MMP13 as a stromal mediator in controlling persistent angiogenesis in skin carcinoma. Carcinogenesis. 2010; 31(7):1175–84. PubMed Central PMCID: PMCPMC2893794. doi: 10.1093/carcin/bgp248 PMID: 19892798

45. Hurwitz H. Integrating the anti-VEGF-A humanized monoclonal antibody bevacizumab with chemotherapy in advanced colorectal cancer. Clin Colorectal Cancer. 2004; 4 Suppl 2:S62–8.

46. Lushchyk T, Amarakoon S, Martinez-Ciriano JP, van den Born Li, Baarsma GS, Missotten T. Bevacizumab in age-related macular degeneration: a randomized controlled trial on the effect of injections every 4 weeks, 6 weeks and 8 weeks. Acta Ophthalmol. 2013; 91(6):e456–61. doi: 10.1111/aos.12119 PMID: 23773796

47. Zehetner C, Kirchmair R, Huber S, Kralinger MT, Kieselbach GF. Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema. The British journal of ophthalmology. 2013; 97(4):454–9. doi: 10.1136/bjophthalmol-2012-302451 PMID: 23385630

48. Pedersen KB, Sjolie AK, Moller F. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration in treatment-naive patients. Acta Ophthalmol. 2009; 87(7):714–9. doi: 10.1111/j.1755-3768.2008.01346.x PMID: 19094171

49. Krebs I, Lie S, Stolba U, Zeiler F, Felke S, Binder S. Efficacy of intravitreal bevacizumab (Avastin) therapy for early and advanced neovascular age-related macular degeneration. Acta Ophthalmol. 2009; 87(6):61–7. doi: 10.1111/j.1755-3768.2008.01312.x PMID: 1937801

50. Bopp S. Anti-VEGF for neovascular ARMD: visual improvement as the goal of therapy? The British journal of ophthalmology. 2007; 91(10):1259–60. PubMed Central PMCID: PMCPMC2001031. doi: 10.1136/bjophthalmol-2007-302451 PMID: 17895411

51. Smit DP, Meyer D. Intravitreal bevacizumab: an analysis of the evidence. Clin Ophthalmol. 2007; 1(3):273–84. PubMed Central PMCID: PMCPMC2701127. PMID: 19668481

52. Motarjemezadeh Q, Aidenloo NS, Sepehri S. A comparative study of different concentrations of topical bevacizumab on the recurrence rate of excised primary pterygium: a short-term follow-up study. Int Ophthalmol. 2016; 36(1):x:1755-3768.2008.01346.x PMID: 19094171

53. Kasetsuwan N, Reinprayoon U, Satitpitalul V. Prevention of recurrent pterygium with topical bevacizumab 0.05% eye drops: a randomized controlled trial. Clin Ther. 2015; 37(10):2347–51. doi: 10.1016/j.clinthera.2015.08.023 PMID: 26409291

54. Nava-Castaneda A, Ulloa-Orozco I, Garnica-Hayashi L, Hernandez-Orgaz J, Jimenez-Martinez MC, Garfias Y. Triple subconjunctival bevacizumab injection for early corneal recurrent pterygium: one-year follow-up. J Ocul Pharmacol Ther. 2015; 31(2):106–13. PubMed Central PMCID: PMCPMC4346374. doi: 10.1089/jop.2014.0060 PMID: 25369364

55. Bayar SA, Kucukerdonmez C, Oner O, Akova YA. Subconjunctival bevacizumab in the impending recurrent pterygium. Int Ophthalmol. 2014; 34(3):541–7. doi: 10.1007/s10792-013-9852-1 PMID: 24026871

56. Peng ML, Tsai YY, Tung JN, Chiang CC, Huang YC, Lee H, et al. Vascular endothelial growth factor gene polymorphism and protein expression in the pathogenesis of pterygium. The British journal of ophthalmology. 2014; 98(4):556–61. doi: 10.1136/bjophthalmol-2013-303436 PMID: 24123908

57. Hu Q, Qiao Y, Nie X, Cheng X, Ma Y. Bevacizumab in the treatment of pterygium: a meta-analysis. Cornea. 2014; 33(2):154–60. doi: 10.1097/ICO.000000000000037 PMID: 24326333

58. Besharati MR, Manaviat MR, Souzani A. Subconjunctival bevacizumab injection in treatment of pterygium. Acta Med Iran. 2011; 49(3):179–83. PMID: 21681707

59. Ziaei M, Manzouri B. Topical cyclosporine in corneal transplantation. Cornea. 2015; 34(1):110–5. doi: 10.1097/ICO.0000000000000291 PMID: 25357076

60. Holland EJ, Olsen TW, Ketcham JM, Florine C, Krachmer JH, Purcell JJ, et al. Topical cyclosporin A in the treatment of anterior segment inflammatory disease. Cornea. 1993; 12(5):413–9. PMID: 8306663

61. de Rojas Silva MV, Rodriguez-Ares MT, Sanchez-Salorio M, Lamas Diaz MJ, Cuevas Alvarez J, Vila Jato JL, et al. Efficacy of subconjunctival cyclosporin-containing microspheres on keratoplasty rejection in the rabbit. Graefes Arch Clin Exp Ophthalmol. 1999; 237(10):840–7. doi: 10.1007/s004170050276 PMID: 10502059

62. Matsuda S, Koyasu S. Mechanisms of action of cyclosporine. Immunopharmacology. 2000; 47(2–3):119–25. PMID: 10878286

63. Yalcin Tok O, Burcu Nurozler A, Ergun G, Akbas Kocaoglu F, Duman S. Topical cyclosporine A in the prevention of pterygium recurrence. Ophthalmologica. 2008; 222(6):391–6. doi: 10.1159/000151740 PMID: 18765950
64. Turan-Vural E, Torun-Acar B, Kivanc SA, Acar S. The effect of topical 0.05% cyclosporine on recurrence following pterygium surgery. Clin Ophthalmol. 2011; 5:881–5. PubMed Central PMCID: PMC3133005. doi: 10.2147/OPHT.S19469 PMID: 21760716

65. Ozulkan K, Koc M, Ayar O, Hasiripi H. Topical cyclosporine A administration after pterygium surgery. Eur J Ophthalmol. 2012; 22 Suppl 7:S5–10.

66. Hwang S, Choi S. A Comparative Study of Topical Mitomycin C, Cyclosporine, and Bevacizumab after Primary Pterygium Surgery. Korean J Ophthalmol. 2015; 29(6):375–81. PubMed Central PMCID: PMC4668252. doi: 10.3341/kjo.2015.29.6.375 PMID: 26635453

67. Viveiros MM, Kakizaki FY, Hercules LA, Padovani CR, Candeias JM, Schellini SA. In vitro study of cyclosporine A 0.05% on primary and recurrent pterygium fibroblasts. Int Ophthalmol. 2016; 36(2):237–42. doi: 10.1007/s10792-015-0106-2 PMID: 26260358

68. Nacev BA, Liu JO. Synergistic inhibition of endothelial cell proliferation, tube formation, and sprouting by cyclosporin A and itraconazole. PLoS One. 2011; 6(9):e24793. PubMed Central PMCID: PMC3182171. doi: 10.1371/journal.pone.0024793 PMID: 21969860

69. Secchi AG, Tognon MS, Leonardi A. Topical use of cyclosporine in the treatment of vernal keratoconjunctivitis. American journal of ophthalmology. 1990; 110(6):641–5. PMID: 2248328

70. Zhao JC, Jin XY. Immunological analysis and treatment of Mooren's ulcer with cyclosporin A applied topically. Cornea. 1993; 12(6):481–8. PMID: 8261778

71. Gunduz K, Ozdemir O. Topical cyclosporin as an adjunct to topical acyclovir treatment in herpetic stromal keratitis. Ophthalmic Res. 1997; 29(6):405–8. PMID: 9380342

72. Tatlipinar S, Akpek EK. Topical ciclosporin in the treatment of ocular surface disorders. The British journal of ophthalmology. 2005; 89(10):1363–7. PubMed Central PMCID: PMC1772855. doi: 10.1136/bjo.2005.070888 PMID: 16170133

73. Utines C, Stern M, Akpek EK. Clinical review: topical ophthalmic use of cyclosporin A. Ocul Immunol Inflamm. 2010; 18(5):352–61. doi: 10.3109/09273948.2010.498657 PMID: 20735287

74. Sacchetti M, Mantelli F, Lambiase A, Mastropasqua A, Merlo D, Bonini S. Systematic review of randomised clinical trials on topical ciclosporin A for the treatment of dry eye disease. The British journal of ophthalmology. 2014; 98(9):1016–22. doi: 10.1136/bjophthalmol-2013-304072 PMID: 24344232

75. Kim YH, Jung JC, Jung SY, Kim YI, Lee KW, Park YJ. Cyclosporine A Downregulates MMP-3 and MMP-13 Expression in Cultured Pterygium Fibroblasts. Cornea. 2015; 34(9):1137–43. doi: 10.1097/ICO.0000000000000477 PMID: 26057330

76. Park YM, Kim CD, Lee JS. Effect of Bevacizumab on Human Tenon's Fibroblasts Cultured from Primary and Recurrent Pterygium. Korean J Physiol Pharmacol. 2015; 19(4):357–63. PubMed Central PMCID: PMC4499648. doi: 10.4196/kjpp.2015.19.4.357 PMID: 26170740

77. Fang C, Illingworth CD, Qian L, Wormstone IM. Serum deprivation can suppress receptor-mediated calcium signaling in pterygium-derived fibroblasts. Invest Ophthalmol Vis Sci. 2013; 54(7):4563–70. doi: 10.1167/iovs.13-11604 PMID: 23761089

78. Acar BT, Hallis E, Acar S. The effect of different doses of subconjunctival bevacizumab injection on corneal neovascularization. Int Ophthalmol. 2013; 33(5):507–13. doi: 10.1007/s10792-013-9732-8 PMID: 23404727

79. Bahar I, Kaiserman I, McAllum P, Rootman D, Slomovic A. Subconjunctival bevacizumab injection for corneal neovascularization in recurrent pterygium. Curr Eye Res. 2008; 33(1):23–8. doi: 10.1080/0271368807199101 PMID: 18214740

80. Kim HH, Mun HJ, Park YJ, Shin JP. Conjunctival autograft using a fibrin adhesive in pterygium surgery. Korean J Ophthalmol. 2008; 22(3):147–54. doi: 10.3341/kjo.2008.22.3.147 PMID: 18784440

81. Hercules LA, Viveiros MM, Schellini SA, Candeias J, Padovani CR. [Exposure of Tenon's capsule fibroblasts of pterygium to cyclosporin 0.05%]. Arq Bras Oftalmol. 2006; 69(6):831–5. PMID: 17273676

82. Chao SC, Hu DN, Yang PY, Lin CY, Yang SF. Overexpression of urokinase-type plasminogen activator in pterygia and pterygium fibroblasts. Mol Vis. 2011; 17:23–31. PubMed Central PMCID: PMC3017801. doi: 10.12299/2011

83. Dake Y, Mukae R, Soda Y, Kaneko M, Amemiya T. Immunohistochemical localization of collagen types I, II, III, and IV in pterygium tissues. Acta Histochem. 1989; 87(1):71–4. doi: 10.1016/S0001-2121(89)80035-2 PMID: 2513700

84. Di Girolamo N, Chui J, Coronee MT, Wakefield D. Pathogenesis of pterygia: role of cytokines, growth factors, and matrix metalloproteinases. Prog Retin Eye Res. 2004; 23(2):195–228. doi: 10.1016/j.preteyeres.2004.02.002 PMID: 15094131
85. Woessner JF Jr. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J. 1991; 5(8):2145–54. PMID: 1850705

86. Zitka O, Kukacka J, Krizkova S, Huska D, Adam V, Masarik M, et al. Matrix metalloproteinases. Curr Med Chem. 2010; 17(31):3751–68. PMID: 20846107

87. Brinckerhoff CE, Rutter JL, Benbow U. Interstitial collagenases as markers of tumor progression. Clin Cancer Res. 2000; 6(12):4823–30. PMID: 11156241

88. Sage EH, Reed M, Funk SE, Truong T, Steadele M, Puolakkainen P, et al. Cleavage of the matricellular protein SPARC by matrix metalloproteinase 3 produces polypeptides that influence angiogenesis. J Biol Chem. 2003; 278(39):37849–57. doi: 10.1074/jbc.M302946200 PMID: 12867428

89. Liu W, Sha X, Wen Y, Zhao W, Luo W, Hua Z. Effect of Avastin on the migration and invasion of pterygium fibroblasts. Eye Sci. 2014; 29(4):214–8. PMID: 26016073

90. Leippi S, Greinh F, Geering G. [Antiangiogenic therapy for pterygium recurrence]. Ophthalmologe. 2009; 106(5):413–9. doi: 10.1007/s00347-009-1938-y PMID: 19418056

91. Lekhanont K, Patarakittam T, Thongphiew P, Suwan-apichon O, Hanutsaha P. Randomized controlled trial of subconjunctival bevacizumab injection in impending recurrent pterygium: a pilot study. Cornea. 2012; 31(2):155–61. doi: 10.1097/ICO.0b013e3182151e0e PMID: 22081150

92. Ozgurhan EB, Agca A, Kara N, Yüksel K, Demircan A, Demirok A. Topical application of bevacizumab as an adjunct to recurrent pterygium surgery. Cornea. 2013; 32(6):835–8. doi: 10.1097/ICO.0b013e31827724de PMID: 23187164

93. Ozsutcu M, Ayintap E, Akkan JC, Koytak A, Aras C. Repeated bevacizumab injections versus mitomycin C in rotational conjunctival flap for prevention of pterygium recurrence. Indian J Ophthalmol. 2014; 62(4):407–11. PubMed Central PMCID: PMCPMC4064213. doi: 10.4103/0301-4738.120220 PMID: 24178405

94. Singh P, Sarkar L, Sethi HS, Gupta VS. A randomized controlled prospective study to assess the role of subconjunctival bevacizumab in primary pterygium surgery in Indian patients. Indian J Ophthalmol. 2015; 63(10):779–84. PubMed Central PMCID: PMCPMC4728977. doi: 10.4103/0301-4738.171508 PMID: 26655003

95. Aydin A, Karadayi K, Aykan U, Can G, Colakoglu K, Bilge AH. [Effectiveness of topical ciclosporin A treatment after excision of primary pterygium and limbal conjunctival autograft]. J Fr Ophtalmol. 2008; 31(7):699–704. PMID: 18971855

96. Di Girolamo N, Kumar RK, Coroneo MT, Wakefield D. UVB-mediated induction of interleukin-6 and -8 in pterygia and cultured human pterygium epithelial cells. Invest Ophthalmol Vis Sci. 2002; 43(11):3430–7. PMID: 12407153

97. Nakamura M, Nishida T. Differential effects of epidermal growth factor and interleukin 6 on corneal epithelial cells and vascular endothelial cells. Cornea. 1999; 18(4):452–8. PMID: 10422859

98. Marionnet AV, Chardonnet Y, Viac J, Schmitt D. Differences in responses of interleukin-1 and tumor necrosis factor alpha production and secretion to cyclosporin-A and ultraviolet B-irradiation by normal and transformed keratinocyte cultures. Exp Dermatol. 1997; 6(1):22–8. PMID: 9067703

99. Strong B, Farley W, Stern ME, Pfugfelder SC. Topical cyclosporine inhibits conjunctival epithelial apoptosis in experimental murine keratoconjunctivitis sicca. Cornea. 2005; 24(1):80–5. PMID: 15604871

100. Goldfield AE, Flemington EK, Boussiotes VA, Theodos CM, Titus RG, Strominger JL, et al. Transcription of the tumor necrosis factor alpha gene is rapidly induced by anti-immunoglobulin and blocked by cyclosporin A and FK506 in human B cells. Proc Natl Acad Sci U S A. 1992; 89(24):12198–201. PubMed Central PMCID: PMCPMC50726. PMID: 1281550

101. Pucci N, Novembre E, Cianferoni A, Lombardi E, Bernardini R, Caputo R, et al. Efficacy and safety of cyclosporine eye drops in vernal keratoconjunctivitis. Ann Allergy Asthma Immunol. 2002; 89(3):298–303. doi: 10.1016/S1081-1206(10)61958-8 PMID: 12269651

102. Al Fayez MF. Limbal versus conjunctival autograft transplantation for advanced and recurrent pterygium. Ophthalmology. 2002; 109(9):1752–5. PMID: 12208727